Akt

PKB; Protein kinase B

Akt

Akt Isoform Specific Products:

Akt Isoform Comparison

Akt Related Products (650)
Recombinant Proteins (6)
Antibodies (11)
Akt Isoform Comparison

By Effects:	Inhibitors (459)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N0103A

Sophocarpine monohydrate	Inhibitor	99.91%
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage.

HY-N4247

Kuwanon G	Inhibitor	99.52%
Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis.

HY-156831

Lixosicone	Inhibitor	99.39%
Lixosicone is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). Lixosicone plays an important role in Cannabis use disorder (CUD).

HY-N4182

Licochalcone E	Inhibitor	99.63%
Licochalcone E, a flavonoid compound isolated from Glycyrrhiza uralensis, inhibits NF-κB and AP-1 transcriptional activity through the inhibition of AKT and MAPK activation.

HY-148877

AT-533	Inhibitor	98.86%
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).

HY-12400

GSK3182571	Inhibitor	99.75%
GSK3182571 is a non-selective broad-spectrum kinase inhibitor with similar structure to CTx-0294885 (HY-15985). GSK3182571 can induce changes in the thermostability of target proteins in cells. GSK3182571 can be used to explore the effects of drugs on kinase networks and off-target effects in leukemia cell models.

HY-N6843

Arnicolide D	Inhibitor	99.69%
Arnicolide D is a sesquiterpene lactone that can be isolated from Centipeda minima. Arnicolide D is cytotoxic to tumor cells and can induce cell cycle arrest, apoptosis, and oncosis in tumor cells. Arnicolide D has anti-tumor activity.

HY-N2232

N-Feruloyloctopamine	Inhibitor	99.91%
N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases the phosphorylation levels of Akt and p38 MAPK.

HY-N2112

Glaucocalyxin A	Inhibitor	99.39%
Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect.

HY-119751

Hematein	Inhibitor
Hematein is a oxidation product of hematoxylin acted as a dye. Hematein is an allosteric casein kinase II inhibitor with an IC₅₀ of 0.74 μM. Hematein inhibits Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway and increases apoptosis in lung cancer cells.

HY-13736A

Quinagolide hydrochloride	Inhibitor	99.69%
Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer.

HY-50862

Akt1/Akt2-IN-1	Inhibitor	99.30%
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of Akt1 (IC₅₀=3.5 nM) and Akt2 (IC₅₀=42 nM), with potent and balanced activity.

HY-N0534

Vitexin-2"-O-rhamnoside	Inhibitor	99.36%
Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC₅₀ of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases.

HY-19982

AKT-IN-6	Inhibitor	99.08%
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

HY-109179

Itacnosertib	Inhibitor	99.06%
Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC₅₀=8 nM) and JAK2 (IC₅₀=8540 nM). Itacnosertib exhibits anti-leukemic activity.

HY-13254A

A-674563 hydrochloride	Inhibitor	99.86%
A-674563 hydrochloride is a potent and selective Akt1 inhibitor with K_i of 11 nM.

HY-N2132

Flavokawain B	Inhibitor	99.99%
Flavokawain B (Flavokavain B) is an orally active chalcone. Flavokawain B results in activation of caspase-9, -3 and -8, cleavage of PARP. Flavokawain B down-regulates Bcl-2 with concomitant increase in Bax level. Flavokawain B inhibits NF-κB, PI3K/Akt and MAPK signaling pathway. Flavokawain B exhibits Apoptotic effects. Flavokawain B inhibits MMP-9 and promotes ROS generation. Flavokawain B inhibits multiple tumors and inflammation.

HY-N6588

3,4,5-Tricaffeoylquinic acid	Inhibitor	98.71%
3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways. 3,4,5-Tricaffeoylquinic acid induces cell cycle arrest at G0/G1, actin cytoskeleton organization, chromatin remodeling, neuronal differentiation, and bone morphogenetic protein signaling in human neural stem cells. 3,4,5-Tricaffeoylquinic acid has the potential for the research of aging-associated diseases.

HY-B0380A

Trimebutine maleate	Inhibitor	99.91%
Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca²⁺ channels and large-conductance calcium-activated potassium channels (BK_Ca channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS).

HY-19719A

Miransertib hydrochloride	Inhibitor	99.74%
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research. Miransertib hydrochloride is effective against *Leishmania*.

MK-2206 dihydrochloride			Akt2, IC₅₀: 12 nM	Akt3, IC₅₀: 65 nM	99.99%
Capivasertib			Akt2, IC₅₀: 7 nM	Akt3, IC₅₀: 7 nM	99.95%
Ipatasertib			Akt2, IC₅₀: 18 nM	Akt3, IC₅₀: 8 nM	99.88%
Oridonin			Akt2, IC₅₀: 8.9 μM		99.89%
AKT inhibitor VIII			Akt2, IC₅₀: 210 nM	Akt3, IC₅₀: 2119 nM	98.97%
GSK-690693			Akt2, IC₅₀: 13 nM	Akt3, IC₅₀: 9 nM	99.03%
Miransertib			Akt2, IC₅₀: 14 nM	Akt3, IC₅₀: 8.1 nM	99.32%
Afuresertib			Akt2, Ki: 2 nM	Akt3, Ki: 2.6 nM	99.53%
Uprosertib			Akt2, IC₅₀: 328 nM	Akt3, IC₅₀: 38 nM	99.93%
Thymoquinone	Akt				99.80%
Rizavasertib			Akt2, Ki: 160 pM	Akt3, Ki: 160 pM	99.71%
Triciribine	Akt, IC₅₀: 130 nM (cell assay)				99.81%
BAY1125976			Akt2, IC₅₀: 18 nM (at 10 μM ATP)	Akt3, IC₅₀: 427 nM (at 10 μM ATP)	99.52%
LM22B-10	Akt				99.92%
Ipatasertib dihydrochloride			Akt2, IC₅₀: 18 nM	Akt3, IC₅₀: 8 nM	99.27%
Engasertib			Akt2, IC₅₀: 0.09 μM	Akt3, IC₅₀: 2.75 μM	99.65%
AT13148			Akt2, IC₅₀: 402 nM	Akt3, IC₅₀: 50 nM	99.20%
AT7867			Akt2, IC₅₀: 17 nM	Akt3, IC₅₀: 47 nM	99.88%
INY-03-041			Akt2, IC₅₀: 6.8 nM	Akt3, IC₅₀: 3.5 nM	99.74%
CCT128930			Akt2, IC₅₀: 6 nM		99.69%
H-Ile-Lys-Val-Ala-Val-OH	Akt				99.42%
MK-2206		Akt1, IC₅₀: 8 nM	Akt2, IC₅₀: 12 nM	Akt3, IC₅₀: 65 nM	99.72%
Vevorisertib trihydrochloride			Akt2, IC₅₀: 0.81 nM	Akt3, IC₅₀: 1.31 nM	99.13%
Pifusertib hydrochloride			Akt2, IC₅₀: 1.6 nM	Akt3, IC₅₀: 44 nM
Serplulimab		Akt1	Akt2	Akt3	99.30%
M2698				Akt3, IC₅₀: 1 nM	99.87%
Afuresertib hydrochloride			Akt2, Ki: 2 nM	Akt3, Ki: 2.6 nM	99.95%
MS170			Akt2, Kd: 77 nM	Akt3, Kd: 6.5 nM	99.72%
AT7867 dihydrochloride			Akt2, IC₅₀: 17 nM	Akt3, IC₅₀: 47 nM	99.75%
AT-533	Akt				98.86%
4-Methylbenzylidene camphor	Akt				99.87%
Akt1/Akt2-IN-1			Akt2, IC₅₀: 42 nM		99.30%
AKT-IN-6			Akt2	Akt3	99.08%
Miransertib hydrochloride			Akt2, IC₅₀: 174 nM	Akt3, IC₅₀: 8.1 nM	99.74%
3CAI			Akt2		98.32%
Deltonin	Akt				99.94%
CCT128930 hydrochloride			Akt2, IC₅₀: 6 nM		98.97%
INY-03-041 trihydrochloride		Akt1, IC₅₀: 2.0 nM	Akt2, IC₅₀: 6.8 nM	Akt3, IC₅₀: 3.5 nM	99.27%
Isoprocurcumenol	Akt
Hu7691			Akt2, IC₅₀: 97.5 nM	Akt3, IC₅₀: 28 nM	99.91%
AKT-IN-3			Akt2, IC₅₀: 1.2 nM	Akt3, IC₅₀: 1.7 nM	99.29%
PTP1B-IN-24	Akt, IC₅₀: 1.4 μM
Akt1/Akt2-IN-2		Akt1, IC₅₀: 138 nM	Akt2, IC₅₀: 212 nM	Akt3, IC₅₀: 7.2 mM	98.57%
MS15			Akt2, IC₅₀: 90 ± 2.8 nM	Akt3, IC₅₀: 544 ± 2.9 nM
Vevorisertib			Akt2, IC₅₀: 0.81 nM	Akt3, IC₅₀: 1.31 nM	98.03%
Pifusertib			Akt2, IC₅₀: 1.6 nM	Akt3, IC₅₀: 44 nM
Coelonin	Akt				≥98.0%
Akt1&PKA-IN-1	Akt, IC₅₀: 0.11 μM
Akt1&PKA-IN-2		Akt1, IC₅₀: 0.007 μM
AKT1-IN-9		AKT1(E17K)
Hu7691 free base			Akt2, IC₅₀: 97.5 nM	Akt3, IC₅₀: 28 nM
MS98			Akt2, : 140 nM	Akt3, : 8.1 nM
MK-2206 free base			Akt2, IC₅₀: 12 nM	Akt3, IC₅₀: 65 nM
AKT-IN-5			Akt2, IC₅₀: 400 nM
TRPM7-IN-1	Akt
Gamendazole		Akt1			99.44%
AKT-IN-8			Akt2, IC₅₀: 2.44 nM	Akt3, IC₅₀: 9.47 nM
PD-1/PD-L1-IN-54	Akt
AKT-IN-13			Akt2, IC₅₀: 2.4 nM	Akt3, IC₅₀: 0.3 nM
Eudebeiolide B	Akt
Tanshinol borneol ester	Akt
Akt1-IN-5		Akt1, IC₅₀: <15 nM
Ipatasertib tosylate		Akt1, IC₅₀: 5 nM	Akt2, IC₅₀: 18 nM	Akt3, IC₅₀: 8 nM
Akt1-IN-8		Akt1, IC₅₀: 8.8 nM
Akt1-IN-6		Akt1, IC₅₀: <15 nM
Akt1-IN-7		Akt1, IC₅₀: <15 nM
Akt1-IN-4		Akt1
AKT-IN-18	Akt, IC₅₀: 69.45 μM
Uprosertib hydrochloride			Akt2, IC₅₀: 328 nM	Akt3, IC₅₀: 38 nM
Akt1-IN-2		Akt1, IC₅₀: 4.6 μM	Akt2, IC₅₀: >250 μM	Akt3, IC₅₀: >250 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.

Akt

Akt

Akt Isoform Specific Products:

Akt Isoform Specific Products:

Akt Related Products (650)

Recombinant Proteins (6)

Antibodies (11)

Akt Isoform Comparison

Akt Related Products (650):